Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
New York, USA, April 23, 2026 (GLOBE NEWSWIRE) -- Global Perfusion Systems Market to Register Incremental Growth at a CAGR of ~5% by 2034 | DelveInsight The global perfusion systems market is...
-
Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the...
-
Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Biologics Active Pharmaceutical Ingredient (API) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The biologics active...
-
Washington, DC, April 23, 2026 (GLOBE NEWSWIRE) -- For the millions of people living with nasal polyps, getting the right diagnosis and accessing effective treatment can take years. Today, on...
-
T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA Paris, le 23 avril 2026 Ventes du T1 en progression de 13,6 % à TCC1 et BNPA2 des activités de 1,88 euro Les ventes des...
-
Q1 2026: double-digit sales and business EPS growth Paris, April 23, 2026 Q1 sales growth of 13.6% at CER1 and business earnings per share (EPS)2 of €1.88 Pharma launches sales increased by 49.6%,...
-
Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée ...
-
Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with...
-
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin...
-
New York, USA, April 22, 2026 (GLOBE NEWSWIRE) -- Global Respiratory Care Devices Market to Grow at a Substantial Growth Rate of ~8% by 2034 | DelveInsight The respiratory care devices market is...